b'Table 2: Adverse Reactions ( 10%) in Patients Who Received INQOVI10Includes arthralgia, back pain, neck pain, joint stiffness, pain in jaw, in Pooled Safety Population joint swelling, bursitis, joint range of motion decreased, and joint injury Intravenous11 Includes dyspnea, dyspnea exertional, hypoxia, wheezing, chronic INQOVI DecitabineINQOVI 12 obstructive pulmonary disease, and tachypnoea Cycle 1Cycle 1All Cycles Includes cough and productive cough N=107 N=106 N=208 13 Includes maculo-papular rash, rash, erythema, skin lesion, folliculitis, dermatitis, dermatitis acneiform, eczema, erythema multiforme, rash AllGradesAllGradesAllGrades erythematous, seborrheic keratosis, skin ulcer, dermatitis allergic, Grades3-4 Grades3-4Grades3-4 dermatitis contact, eczema nummular, genital erythema, rash papular, Adverse Reactions (%) (%) (%) (%) (%) (%) rash pruritic, rash pustular, seborrheic dermatitis, skin exfoliation, Nervous system disorders skin irritation, stasis dermatitis, and ulcerative keratitis 14 14 Includes dizziness, vertigo, postural dizziness, and positional vertigo Dizziness 16 1 11 0 33 2 15 Includes headache, sinus pain, and sinus headache Headache15 22 0 13 0 30 0 16 Includes hypoesthesia, paresthesia, neuropathy peripheral, gait Neuropathy16 4 0 8 0 13 0 disturbance, peripheral sensory neuropathy, ataxia, balance disorder, Metabolism and nutritional disorders 17 brachial plexopathy, carpal tunnel syndrome, and radicular painIncludes upper respiratory tract infection, nasopharyngitis, sinusitis, Decreased appetite 10 1 6 0 24 2 and viral upper respiratory tract infection Infections and infestations 18 Includes pneumonia, pneumonitis, atypical pneumonia, and lung Upper respiratory infection tract infection17 6 0 3 0 23 1 19 Includes sepsis, bacteremia, septic shock, endocarditis, pseudomonal Pneumonia 7 7 7 5 21 15 20 bacteremia, and staphylococcal bacteremia 18Includes cellulitis, catheter site cellulitis, and infected bite Sepsis19 6 6 2 1 14 11 21 Includes blood creatinine increased, acute kidney injury, blood urea Cellulitis20 4 1 3 2 12 5 increased, blood creatine increased, and renal failure Investigations 22 Includes hypotension, blood pressure decreased, and cardiogenic shock Renal impairment21 9 0 8 1 18 0 23 Includes sinus tachycardia, atrial fibrillation, bradycardia, tachycardia, Weight decreased 5 0 3 0 10 1 atrial flutter, sinus bradycardia, and conduction disorder Injury, poisoning, and procedural complications Clinically relevant adverse reactions in 10% of patients who received Fall 4 0 1 0 12 1 INQOVI included: Psychiatric disorders \x7f Acute febrile neutrophilic dermatosis (Sweets syndrome) (1%) \x7f Tumor lysis syndrome (0.5%) Insomnia 6 0 2 0 12 0.5 Table 3: Select Laboratory Abnormalities ( 20%) Worsening from Vascular disorders Baseline in Patients Who Received INQOVI in Pooled Safety PopulationHypotension22 4 0 6 1 11 2 Intravenous Cardiac Disorders INQOVI DecitabineINQOVIArrhythmia 3 0 2 0 11 1 Cycle 1 Cycle 1 All Cycles23 Includes adverse reactions that occurred during all cycles, includingAllGrades AllGrades AllGrades during treatment with 1 cycle of intravenous decitabine.Grades 3-4Grades 3-4Grades 3-4 Lab Abnormality* (%) (%) (%) (%) (%) (%)1Includes fatigue, asthenia, and lethargy 2Includes contusion, epistaxis, petechiae, hematuria, conjunctivalHematology hemorrhage, mouth hemorrhage, purpura, angina bullosaLeukocytes decreased 79 65 77 59 87 81hemorrhagica, gingival bleeding, hematoma, hemoptysis, eyePlatelet count decreased 79 65 77 67 82 76contusion, hemorrhagic diathesis, increased tendency to bruise,Neutrophil count70 65 62 59 73 71vaginal hemorrhage, abdominal wall hematoma, blood blister, bonedecreasedcontusion, catheter site bruise, ecchymosis, genital hemorrhage,intra-abdominal hematoma, oral mucosa hematoma, periorbitalHemoglobin decreased 58 41 59 36 71 55hemorrhage, procedural hemorrhage, pulmonary alveolar hemorrhage,Chemistryretinal hemorrhage, scleral hemorrhage, thrombotic thrombocytopenicGlucose increased 19 0 11 0 54 7purpura, tongue hemorrhage, and vessel puncture site hemorrhage 3Includes edema peripheral, peripheral swelling, swelling face, fluidAlbumin decreased 22 1 20 0 45 2overload, localized edema, face edema, edema, eye swelling, eyelidAlkaline phosphatase22 1 12 0 42 0.5edema, fluid retention, periorbital swelling, scrotal edema, scrotalincreasedswelling, and swellingGlucose decreased 14 0 17 0 40 14Includes constipation and feces hard 5Includes oropharyngeal pain, stomatitis, mouth ulceration, proctalgia,Alanine13 1 7 0 37 2oral pain, gingivitis, oral disorder, gingival pain, colitis, glossodynia,aminotransferase mouth swelling, pharyngitis, proctitis, duodenitis, enteritis, gingivalincreaseddiscomfort, gingival swelling, lip disorder, lip ulceration, mucosalSodium decreased 9 2 8 0 30 4ulceration, nasal ulcer, noninfective gingivitis, oral mucosal blistering,Calcium decreased 16 0 12 0 30 2oral mucosal erythema, pharyngeal erythema, pharyngeal ulceration,Aspartate6 1 2 0 30 26 tongue ulceration, and vulvitisaminotransferase 7 Includes diarrhea and feces softincreasedIncludes alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased,Creatinine increased 7 0 8 0 29 0.5gamma-glutamyltransferase increased, liver function test increased,* Includes any lab abnormalities that worsened by one or more grades. and transaminases increasedGrade 3-4 includes any lab abnormalities that worsened to Grade 3 or 8Includes abdominal pain, abdominal pain upper, abdominal pain lower,Grade 4. epigastric discomfort, and abdominal discomfortThe denominator used to calculate the rate varied from 103 to 107 for 9Includes myalgia, pain in extremity, muscle spasms, pain, musculoskeletalINQOVI Cycle 1, from 102 to 106 for Intravenous Decitabine Cycle and pain, non-cardiac chest pain, muscular weakness, musculoskeletalfrom 203 to 208 for INQOVI All Cycles based on the number of patients chest pain, flank pain, musculoskeletal stiffness, muscle strain, andwith a baseline value and at least one post-treatment value.musculoskeletal discomfort'